ご挨拶

私は医師になって令和3年で29年になります。長年、呼吸器専門病院で勤務し、呼吸器疾患の診療に携わってきました。しかし年齢を重ねるにつれて次第に管理的な仕事が増え、患者さんと直接関わる機会が減ってきました。お一人おひとりの患者さんに向き合って診療を続けていきたいという思いから、このたび地元の八尾市で開業することにいたしました。
医療の進歩に遅れないよう日々勉強し患者さんに良い医療を提供することで、地域社会に貢献できるようにスタッフ一同努力して参ります。

 院長 北田 清悟

略歴

  • 大阪府八尾市の生まれ
  • 平成5年 三重大学医学部卒業
  • 大阪大学医学部附属病院第三内科
  • 大阪逓信病院第二内科
  • 国立病院機構刀根山病院 呼吸器内科部長
  • 八尾徳洲会総合病院 呼吸器内科部長
  • 令和3年 4月 北田内科・呼吸器内科 開設

資格

  • 医学博士
  • 日本内科学会認定内科医・指導医
  • 日本内科学会総合内科専門医
  • 日本呼吸器学会呼吸器専門医・指導医
  • 結核・抗酸菌症認定医・指導医
  • インフェクションコントロールドクター (ICD)
  • 緩和ケア研修会 修了
  • 呼吸機能身体障害申請指定医

所属学会

  • 日本内科学会
  • 日本呼吸器学会
  • 日本結核・非結核性抗酸菌症学会
  • 日本呼吸器内視鏡学会
  • 日本肺癌学会

専門分野

  • 肺非結核性抗酸菌症・気管支拡張症
  • 気管支喘息
  • COPD
  • 間質性肺炎
  • 慢性呼吸不全

主な英語論文

非結核性抗酸菌症・気管支拡張症

  1. First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacteirum avium complex pulmonary disease. Fukushima K, Kitada S, Komukai S, Kuge T, Matsuki T, Kagawa H, Tsujino K, Miki M, Miki K, Kida H. Sci Rep. 2021 Jan 13;11(1):1178.
  2. Long-Term Treatment Outcome of Progressive Mycobacteirum avium Complex Pulmonary Disease. Fukushima K, Kitada S, Abe Y, Yamamoto Y, Matsuki T, Kagawa H, Oshitani Y, Tsujino K, Yoshimura K, Miki M, Miki K, Kida H. J Clin Med. 2020 May 2;9(5):1315.
  3. Application of a commercial serodiagnostic kit that measures the serum anti-glycopeptidolipid core IgA antibody in Mycobacteirum avium complex pulmonary disease. Kitada S. Respir Investig. 2019 Sep;57(5):410-414.
  4. Diagnostic Validity of Gastric Aspirate Culture in Nontuberculous Mycobacterial Pulmonary Disease. Hara R, Kitada S, Iwai A, Kuge T, Oshitani Y, Kagawa H, Tsujino K, Yoshimura K, Miki M, Miki K, Kida H. Ann Am Thorac Soc. 2020 Dec;17(12):1536-1541.
  5. Characteristic chest CT findings for progressive cavities in Mycobacteirum avium complex pulmonary disease: a retrospective cohort study. Oshitani Y, Kitada S, Edahiro R, Tsujino K, Kagawa H, Yoshimura K, Miki K, Miki M, Kida H. Respir Res. 2020 Jan 8;21(1):10.
  6. The association between erythromycin monotherapy for Mycobacteirum avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study. Hosono Y, Kitada S, Yano Y, Mori M, Miki K, Miki M, Yoshimura K, Kagawa H, Oshitani Y, Yokota S. J Infect Chemother. 2018 May;24(5):353-357.
  7. Whole-genome sequence of the hypervirulent clinical strain Mycobacterium intracellulare M.i.198. Tateishi Y, Kitada S, Miki K, Maekura R, Ogura Y, Ozeki Y, Nishiuchi Y, Niki M, Hayashi T, Hirata K, Kobayashi K, Matsumoto S. J Bacteriol. 2012 Nov;194(22):6336.
  8. Direct detection of Mycobacteirum avium in environmental water and scale samples by loop-mediated isothermal amplification. Nishiuchi Y, Tamaru A, Suzuki Y, Kitada S, Maekura R, Tateishi Y, Niki M, Ogura H, Matsumoto S. J Water Health. 2014 Jun;12(2):211-9.
  9. Serodiagnosis of Mycobacteirum avium complex pulmonary disease in the USA. Kitada S, Levin A, Hiserote M, Harbeck RJ, Czaja CA, Huitt G, Kasperbauer SH, Daley CL. Eur Respir J. 2013 Aug;42(2):454-60.
  10. Serodiagnosis of pulmonary disease due to Mycobacteirum avium complex proven by bronchial wash culture. Kitada S, Kobayashi K, Nishiuchi Y, Fushitani K, Yoshimura K, Tateishi Y, Miki K, Miki M, Hashimoto H, Motone M, Fujikawa T, Hiraga T, Maekura R. Chest. 2010 Jul;138(1):236-7.
  11. Long-term radiographic outcome of nodular bronchiectatic MAC pulmonary disease. Kitada S, Uenami T, Yoshimura K, et al,Int J Tuberc Lung Dis 2012; 16(5): 660-664.
  12. Serological test and chest computed tomography findings in patients with Mycobacterium avium complex lung disease. Kitada S, Nishiuchi Y, Hiraga T, et al. Eur Respir J 2007; 29 (6): 1217-23.
  13. Levels of Antibody against Glycopeptidolipid Core as a Marker for Monitoring Treatment Response in Mycobacteirum avium Complex Pulmonary Disease: a Prospective Cohort Study. Kitada S, Maekura R, Yoshimura K, Miki K, Miki M, Oshitani Y, Nishida K, Sawa N, Mori M, Kobayashi K. J Clin Microbiol. 2017 Mar;55(3):884-892.
  14. The recovery of Mycobacteirum avium-intracellulare complex (MAC) from the residential bathrooms of patients with pulmonary MAC. Nishiuchi Y, Maekura R, Kitada S, Tamaru A, Taguri T, Kira Y, Hiraga T, Hirotani A, Yoshimura K, Miki M, Ito M. Clin Infect Dis. 2007 Aug 1;45(3):347-51.
  15. Serodiagnosis of Mycobacteirum avium-complex pulmonary disease using an enzyme immunoassay kit. Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M, Suzuki K, Takashima T, Nagai T, Sakurabayashi I, Ito M, Maekura R; MAC Serodiagnosis Study Group. Am J Respir Crit Care Med. 2008 Apr 1;177(7):793-7.
  16. Use of glycopeptidolipid core antigen for serodiagnosis of Mycobacteirum avium complex pulmonary disease in immunocompetent patients. Kitada S, Maekura R, Toyoshima N, Naka T, Fujiwara N, Kobayashi M, Yano I, Ito M, Kobayashi K. Clin Diagn Lab Immunol. 2005 Jan;12(1):44-51.
  17. Serodiagnosis of pulmonary disease due to Mycobacteirum avium complex with an enzyme immunoassay that uses a mixture of glycopeptidolipid antigens.Kitada S, Maekura R, Toyoshima N, Fujiwara N, Yano I, Ogura T, Ito M, Kobayashi K. Clin Infect Dis. 2002 Dec 1;35(11):1328-35.

結核

  1. Serum antibody profiles in individuals with latent Mycobacterium tuberculosis infection. Maekura R, Kitada S, Osada-Oka M, Tateishi Y, Ozeki Y, Fujicawa T, Miki M, Jyunnko O, Mori M, Matsumoto S. Microbiol Immunol. 2019 Mar;63(3-4):130-138.
  2. Antigen 85A and mycobacterial DNA-binding protein 1 are targets of immunoglobulin G in individuals with past tuberculosis. Osada-Oka M, Tateishi Y, Hirayama Y, Ozeki Y, Niki M, Kitada S, Maekura R, Tsujimura K, Koide Y, Ohara N, Yamamoto T, Kobayashi K, Matsumoto S. Microbiol Immunol. 2013 Jan;57(1):30-7.
  3. Exertional dyspnea-related acidotic and sympathetic responses in patients with sequelae of pulmonary tuberculosis. Miki K, Maekura R, Hiraga T, Hashimoto H, Kitada S, Miki M, Yoshimura K, Tateishi Y, Sugano T, Motone M. J Physiol Sci. 2010 May;60(3):187-93.
  4. Rapid serodiagnosis of active pulmonary Mycobacterium tuberculosis by analysis of results from multiple antigen-specific tests. Okuda Y, Maekura R, Hirotani A, Kitada S, Yoshimura K, Hiraga T, Yamamoto Y, Itou M, Ogura T, Ogihara T. J Clin Microbiol. 2004 Mar;42(3):1136-41.

COPD 慢性閉塞性肺疾患

  1. A phase II, open-label clinical trial on the combination therapy with medium-chain triglycerides and ghrelin in patients with chronic obstructive pulmonary disease. Miki K, Kitada S, Miki M, Hui SP, Shrestha R, Yoshimura K, Tsujino K, Kagawa H, Oshitani Y, Kida H, Maekura R, Kangawa K. J Physiol Sci. 2019 Nov;69(6):969-979.
  2. Dyspnea and the Varying Pathophysiologic Manifestations of Chronic Obstructive Pulmonary Disease Evaluated by Cardiopulmonary Exercise Testing With Arterial Blood Analysis. Kagawa H, Miki K, Kitada S, Miki M, Yoshimura K, Oshitani Y, Nishida K, Sawa N, Tsujino K, Maekura R. Front Physiol. 2018 Oct 2;9:1293.
  3. Effects of ghrelin treatment on exertional dyspnea in COPD: an exploratory analysis. Miki K, Maekura R, Nagaya N, Miki M, Kitada S, Yoshimura K, Mori M, Kangawa K. J Physiol Sci. 2015 May;65(3):277-84.
  4. Identification of three exercise-induced mortality risk factors in patients with COPD. Yoshimura K, Maekura R, Hiraga T, Miki K, Kitada S, Miki M, Tateishi Y, Mori M. COPD. 2014 Dec;11(6):615-26.
  5. Personalized pulmonary rehabilitation and occupational therapy based on cardiopulmonary exercise testing for patients with advanced chronic obstructive pulmonary disease. Maekura R, Hiraga T, Miki K, Kitada S, Miki M, Yoshimura K, Yamamoto H, Kawabe T, Mori M. Int J Chron Obstruct Pulmon Dis. 2015 Sep 3;10:1787-800.
  6. Effects of ghrelin treatment on exercise capacity in underweight COPD patients: a substudy of a multicenter, randomized, double-blind, placebo-controlled trial of ghrelin treatment. Miki K, Maekura R, Nagaya N, Kitada S, Miki M, Yoshimura K, Tateishi Y, Motone M, Hiraga T, Mori M, Kangawa K. BMC Pulm Med. 2013 Jun 10;13:37.
  7. Effects of tiotropium on sympathetic activation during exercise in stable chronic obstructive pulmonary disease patients. Yoshimura K, Maekura R, Hiraga T, Kitada S, Miki K, Miki M, Tateishi Y. Int J Chron Obstruct Pulmon Dis. 2012;7:109-17.
  8. Effects of oxygen on exertional dyspnoea and exercise performance in patients with chronic obstructive pulmonary disease. Miki K, Maekura R, Hiraga T, Kitada S, Miki M, Yoshimura K, Tateishi Y. Respirology. 2012 Jan;17(1):149-54.
  9. Exercise-induced electrocardiographic changes in patients with chronic respiratory diseases: differential diagnosis by 99mTc-tetrofosmin SPECT. Hirotani A, Maekura R, Okuda Y, Yoshimura K, Moriguchi K, Kitada S, Hiraga T, Ito M, Ogura T, Ogihara T. J Nucl Med. 2003 Mar;44(3):325-30.

間質性肺炎 びまん性肺疾患

  1. Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease:A case report. Kagawa H, Tsujino K, Yamamoto Y, Iwai A, Hara R, Matsuki T, Fukushima K, Oshitani Y, Yoshimura K, Miki M, Miki K, Kitada S, Mori M, Kida H. Respir Med Case Rep. 2020 Feb 1;29:101016.
  2. Three Cases of Idiopathic Diffuse Pulmonary Ossification. Edahiro R, Kurebe H, Nakatsubo S, Hosono Y, Sawa N, Nishida K, Ohara Y, Oshitani Y, Kagawa H, Tsujino K, Yoshimura K, Miki K, Miki M, Kitada S, Mori M. Intern Med. 2019 Feb 15;58(4):545-551.
  3. Congenital cystic adenomatoid malformation in adults detected after infection. Kagawa H, Miki K, Miki M, Urasaki K, Kitada S. Respirol Case Rep. 2018 Sep 14;6(8)
  4. Exogenous lipoid pneumonia caused by repeated sesame oil pulling: a report of two cases. Kuroyama M, Kagawa H, Kitada S, Maekura R, Mori M, Hirano H. BMC Pulm Med. 2015 Oct 30;15:135.
  5. Acidosis and raised norepinephrine levels are associated with exercise dyspnoea in idiopathic pulmonary fibrosis. Miki K, Maekura R, Hiraga T, Hashimoto H, Kitada S, Miki M, Yoshimura K, Tateishi Y, Fushitani K, Motone M. Respirology. 2009 Sep;14(7):1020-6.

気管支喘息

  1. 3. Human airway trypsin-like protease enhances interleukin-8 synthesis in bronchial epithelial cells by activating protease-activated receptor 2. Miki M, Yasuoka S, Tsutsumi R, Nakamura Y, Hajime M, Takeuchi Y, Miki K, Kitada S, Maekura R. Arch Biochem Biophys. 2019 Mar 30;664:167-173.
  2. Improvement of exertional dyspnea and breathing pattern of inspiration to expiration after bronchial thermoplasty. Miki K, Miki M, Yoshimura K, Tsujino K, Kagawa H, Oshitani Y, Ohara Y, Hosono Y, Edahiro R, Kurebe H, Kitada S. Allergy Asthma Clin Immunol. 2018 Oct 29;14:74.

日本語雑誌・書籍

  1. 肺MAC症と抗GPL抗体、分子呼吸器学、2012年
  2. MAC症診断における血清診断法 バイオマーカーになりうるのか、肺MAC症 up to Date、2013年
  3. 非結核性抗酸菌症のバイオマーカー -肺MAC症の血清診断-、Lung perspecitve、2014年
  4. 肺MAC症の診断-血清診断の有用性と問題点、医学のあゆみ、2014年
  5. 肺非結核性抗酸菌症の血清診断の意義、呼吸器内科、2015年
  6. 非結核性抗酸菌症 今日の治療指針 私はこう治療している、2016年
  7. 抗酸菌の血液検査 結核 改訂版、2016年
  8. 肺MAC症の早期診断—鑑別診断(画像・検査)および診断後の対応、日本医事新報、2016年
  9. 非結核性抗酸菌症の血清診断法の意義と問題点、化学療法の領域、2016年
  10. 微生物検査における技術革新 抗GPL-core IgA抗体検査用キット「キャピリア®MAC抗体ELISA」、臨床と微生物、2017年
  11. 抗GPL抗体の基礎と臨床、呼吸器ジャーナル、2018年
  12. 疾患と検査値の推移 肺MAC症におけるGPL core抗体測定と抗体価変動の意義、検査と技術、2019年
  13. 肺非結核性抗酸菌症の血清診断の可能性 呼吸器内科、2020年
  14. 肺マイコバクテリウム・アビウム・コンプレックス感染症、今日の疾患辞典、2020年